TLDR
- Cathie Wood’s ARK Invest added to positions in Figma, Arcturus Therapeutics, and 10x Genomics last week — its only three purchases
- ARK bought 337,381 shares of Figma for over $8.1 million on Friday March 20
- ARK sold 45,998 shares of Circle Internet Group, a crypto-related stock, for nearly $5.9 million across ARKK and ARKW
- Figma stock is down 83% from its 2025 highs despite 40% revenue growth in its latest quarter
- ARK also sold shares in Teradyne, Bullish, Guardant Health, and Butterfly Network last week
Cathie Wood, the founder and CEO of ARK Invest, made just three stock purchases last week as markets fell for the fourth straight week. The three major market indexes all moved lower during that period.
Wood typically buys more aggressively during market pullbacks, so the limited activity stood out to investors.
The three stocks she added to were Figma, Arcturus Therapeutics, and 10x Genomics. At the same time, ARK sold shares in several companies, including Circle Internet Group, a crypto-related stock.
Figma is a cloud-based design platform used for websites, apps, and digital products. ARK bought 337,381 shares of Figma on March 20 across its ARKK and ARKW ETFs, totaling $8,171,367.
The stock has fallen 83% from its peak last summer, after more than quadrupling from its IPO price of $33. Despite the sharp decline, Figma reported 40% revenue growth in its most recent quarter, up from 38% the previous quarter.
Its net dollar-retention rate hit 136%, meaning existing customers spent 36% more on the platform compared to a year earlier. That is the strongest reading on that metric in two years.
Analysts expect revenue growth to slow to 30% this year and 20% next year. Figma has not reported strong profitability, which has weighed on the stock.
ARK Reduces Circle Internet Crypto Stake
On the crypto side, ARK sold 45,998 shares of Circle Internet Group across ARKK and ARKW, totaling $5,902,923. ARK had been reducing its Circle Internet position throughout the week.
Circle Internet is a crypto-linked company known for its role in the USD Coin stablecoin ecosystem.
ARK also sold 19,206 shares of Teradyne for $5,807,894, along with 103,379 shares of Bullish for $4,093,808 and 9,621 shares of Guardant Health for $857,038. ARK sold 182,353 shares of Butterfly Network for $723,941.
Biotech Picks: Arcturus and 10x Genomics
Arcturus Therapeutics uses messenger RNA technology to develop treatments for rare respiratory and liver diseases. ARK bought shares in Arcturus on three of the five trading days last week, most recently purchasing 22,773 shares on Friday for $153,034 through its ARKG ETF.
Revenue at Arcturus has fallen sharply for three straight years and is expected to drop further in 2026. However, the company recently extended its cash runway to at least the second quarter of 2028.
10x Genomics makes life sciences tools, including its Chromium platform for single-cell genomic analysis. ARK bought 192,658 shares last week across ARKK and ARKG for $3,541,054.
The company went public at $38 per share and now trades around half that price. It has never turned a profit, and its own 2026 guidance points to a revenue decline when including licensing income from patent settlements last year.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
